Skip to main content
. 2019 Oct 5;11(10):515. doi: 10.3390/pharmaceutics11100515

Figure 8.

Figure 8

Effect of daily OC 10 mg/kg oral treatment in EF-2 on the recurrence of BT-474 BC cells after primary tumor surgical excision in the nude mouse xenograft model. (A) Recurred mice tumors at the experiment end. Top row: recurred mice tumors of the placebo-treated group. Bottom row: recurred mice tumors of EF-2-treated group. (B) Vertical bars comparing the mean recurrence tumor weight at the end of the experiment. (C) Vertical bars representing the mean recurrence tumor volume at the end of the experiment. (D) Comparison of effects of EF-2 and placebo treatments on the recurrence tumor onset. (E) Body weight monitoring of animals over the duration of the experiment. (F) Recurrence tumor volumes monitoring over the experiment course. Points represent the mean tumor volume of recurred tumors (n = 5) in each experimental group during the treatment period. Error bars indicate SD for n = 5. (G) Comparison of the effects of EF-2 and placebo treatments on the animal organ weights at the end of the experiment. (H) Comparison of the effects of EF-2 and placebo treatments on the serum levels of the recurrence tumor biomarker CA 15-3 at the end of the experiment.